Advanced Pharma CR LLC

1. Eli Lilly and Company $4,303,609 39 payments
2. Eagle Pharmaceuticals, Inc. $2,270,155 19 payments
3. Zogenix Inc. $1,013,034 336 payments
4. Astellas Pharma Inc $683,819 64 payments
5. Amgen Inc. $524,004 9 payments
6. Roche TCRC, Inc. $427,582 28 payments
7. GlaxoSmithKline, LLC. $199,018 19 payments
8. Pfizer Inc. $180,782 21 payments
9. Genentech, Inc. $179,856 26 payments
10. AbbVie, Inc. $169,786 57 payments

1. A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3849891 in Participants With Nonalcoholic Fatty Liver Disease Who Have the Pnpla3 I148m Genotype $1,535,959 6 payments
2. Phase 1, Randomized, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetcs of Three Formulations of Fulvestrant for Injectable Suspension Test Compared to Faslodex Injection Reference Following Single Dose Intramuscu $1,362,686 5 payments
3. Mt-1621 $1,013,034 336 payments
4. Prescreening Study for Patients With Nonalcoholic Fatty Liver Disease (Nafld) Who Are Carriers of the Pnpla3 I148m Allele $1,012,350 2 payments
5. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant After Im Administration $907,470 14 payments
6. A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Ly3849891 in Participants With Nonalcoholic Fatty Liver Disease Who Have the Pnpla3 I148m Genotype $750,133 2 payments
7. A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants with Normal Renal Function and Participants with Various Degrees of Renal Impairment $460,975 1 payment
8. Phase 1 PK Study in Renal Impairment population 2 $427,582 28 payments
9. A Multiple-Dose, Randomized, Placebo-Controlled, Study of Ly3462817 in Patients With Psoriasis $275,240 5 payments
10. Pharmacokinetics of Ly3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function $208,190 2 payments

1. Patient care $1,983,442 16 payments
2. Other $260,213 1 payment
3. Overhead $26,500 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.